Academics To Doctors’ Group: Dump Nemeroff
By Ed Silverman
March 30th, 2012
Here is an irony, the Anxiety Disorders Association of America, which is devoted to combating anxiety, depression and stress-related disorders, is causing some stress and anxiety among academics and physicians. Why? The professional organization recently named Charles Nemeroff, the controversial psychiatry professor, to its board. And so, an Internet petition is now circulating that calls on the ADAA board to swiftly remove Nemeroff before the reputation of the organization and its professionals are sullied. How so? His “track record of unethical behavior that has harmed the standing of our field, the credibility of some of its treatments, and risked the well being of millions of patients,” according to the petition.
For those who may not recall, Nemeroff was an Emory University professor who was sanctioned for failing to disclose that he had accepted about $500,000 in payments from GlaxoSmithKline while he was also the primary investigator for a National Institutes of Health study of the Paxil antidepressant, which is sold by the drugmaker. The details emerged thanks to a US Senate Finance committee probe into undisclosed conflicts of interest. At issue was the extent to which such relationships may unduly influence medical research and practice. The Senate probe reached out like an octopus and ensnared various drugmakers, universities, medical journals and the NIH itself, specifically the National Institutes of Mental Health.
Since then, various drugmakers and institutions have gradually adopted policies concerning disclosure. And, of course, the pharmaceutical industry will be required to publish payments to physicians next year. As for Nemeroff, he now chairs the psychiatry department at the Miller School of Medicine at The University of Miami, where he is, once again, seeking grants from the NIH, according to sources.
Next month, Nemeroff is scheduled to make his first appearance as an ADAA board member when the organization holds its annual meeting. The petition hopes to rescind the decision before his public vetting. “In determining its position on the issue, the (ADAA) board apparently overlooked or questioned the severity of the case against Dr. Nemeroff. Nonetheless, we do not believe the board’s position represents general sentiment within the professional community, nor does it erase the public record upon which many potential supporters of ADAA will determine their opinion. By selecting Dr. Nemeroff to represent the organization at its highest level, the board sends the wrong message to ADAA’s membership and to the public at large regarding the organization’s values and commitment to integrity in patient care, research, and education. ADAA is not immune to the public distrust and decline in professional membership inevitably associated with decay of an organization’s credibility”…
Top Psychiatrist Didn’t Report Drug Makers’ Pay
New York Times
By GARDINER HARRIS
October 3, 2008
One of the nation’s most influential psychiatrists earned more than $2.8 million in consulting arrangements with drug makers between 2000 and 2007, failed to report at least $1.2 million of this income to his university, and violated federal research rules, according to documents provided to Congressional investigators. The psychiatrist, Dr. Charles B. Nemeroff of Emory University, is the most prominent example to date in a series of disclosures that is shaking the world of academic medicine and seems likely to force broad changes in the relationships between doctors and drug makers.
In one telling example, Dr. Nemeroff signed a letter dated July 15, 2004, promising Emory administrators that he would earn less than $10,000 a year from GlaxoSmithKline to comply with federal rules. But on that day, he was at the Four Seasons Resort in Jackson Hole, Wyo., earning $3,000 of what would become $170,000 in income that year from the British drug giant — 17 times the figure he had agreed on…
Dr. Nemeroff was the principal investigator for a five-year, $3.9 million grant financed by the National Institute of Mental Health for which GlaxoSmithKline provided drugs. Income from GlaxoSmithKline of $10,000 or more in any year of the grant — a threshold Dr. Nemeroff crossed in 2003, 2004, 2005 and 2006, records show — would have required Emory to inform the health institutes and manage the conflict or remove Dr. Nemeroff as the investigator. Repeatedly assured by Dr. Nemeroff that he had not crossed this income threshold, Emory did nothing…
Scientific Research Symposium
The Interface of Anxiety Disorders and Medical Disorders: Pathophysiology and Treatment Implications
Friday, April 13
Charles Nemeroff, MD, PhD
The theme for this Scientific Research Symposium is anxiety in medicine, exploring the increased medical vulnerability, and impact on outcomes when patients have stress, anxiety, and related disorders.
But if there’s one thing that the Emory Administration learned in his two decades there, Charlie doesn’t stop. He keeps on going no matter what, so it’s no surprise to see him back on the stage…